• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Iconic Funds Receives Regulatory Approval for and Launches New Fund in Partnership with Coin Metrics

    7/6/21 3:00:00 AM ET
    $CAP
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $CAP alert in real time by email

    FRANKFURT AM MAIN, GERMANY / ACCESSWIRE / July 6, 2021 / Iconic Funds Sicav, Plc., an affiliate of Iconic Funds GmbH (jointly branded as 'Iconic Funds'), has launched a new Professional Investor Fund - named the Iconic CMBI10 Short-Term Momentum Index Fund ('Fund'). The Fund was recently granted a license by the Malta Financial Services Authority ('MFSA'). The new fund marks the beginning of a collaboration between Iconic Funds and Coin Metrics, a leading crypto asset data and analytics provider, as the Fund will seek to replicate one of Coin Metrics' most prominent indices. The Fund is only available to qualifying investors, as defined in the Fund Documents and applicable rules issued by the MFSA.

    The Fund seeks to track the performance of the CMBI10 Short-Term Momentum Index, which includes the top 10 crypto assets by market capitalization. Additionally, the Fund strives to optimize passive returns by depositing coins into staking and interest-bearing accounts with reputable counterparties.

    Coin Metrics' 10 Short-Term Momentum Index aims to reflect the performance of the momentum factor for the Parent Index, the CMBI10 Index. Constituents for momentum indexes are selected based on eligibility criteria and their 10-year expected future market capitalization, as defined in the index methodology. The weight of each crypto asset within the index is dynamic and based on the momentum scores of the asset during the momentum observation period.

    Iconic Funds and Cryptology Asset Group CEO Patrick Lowry said: 'Iconic Funds is committed to providing investors innovative crypto investment strategies through regulated and familiar means. The launch of our newest fund, the Iconic CMBI10 Short-Term Momentum Index Fund, demonstrates our commitment to investors to deliver on this promise with new and exciting crypto investment strategies.'

    Coin Metrics CEO, Timothy Rice, said: 'Through leveraging our unique and broad dataset, Coin Metrics strives to innovate and offer new index products which leverage traditional concepts and/or incorporate new crypto asset native concepts. Working with Iconic Funds, we are thrilled to be launching the Iconic CMBI 10 Short-Term Momentum Index Fund which aspires to capture the upside of an aggressive crypto asset growth index, whilst endeavouring to limit downside volatility.''

    The launch of the Iconic CMBI10 Short-Term Momentum Index Fund marks the second EU-domiciled fund to be launched by the Iconic Funds group, following the Iconic BITA20 XA Index Fund in early 2020. Iconic Funds continues to explore ground-breaking crypto investment strategies with its partners to give investors multiple avenues to access the performance of crypto assets.

    Product Name

    Iconic CMBI10 Short-Term

    Momentum Index Fund

    ISINs

    Share Class A - MT7000030730

    Share Class B - MT7000030748

    Management Fee1.00%
    Performance Fee

    Share Class A - 5.00%

    Share Class B - 10.00%

    Base CurrencyEUR
    Product StructureProfessional Investor Fund
    DomicileMalta
    ManagerIconic Funds Sicav, Plc.
    AdministratorTrident Fund Services (Malta) Limited
    AuditorBDO Malta
    CustodianCoinbase Custody International Ltd
    Fund Launch DateJuly 6, 2021

    Important Notices:

    Iconic Funds Sicav, Plc. and the Fund are licensed as a Professional Investor Fund available to qualifying investors by the MFSA in terms of the Investment Services Act (Chapter 370, Laws of Malta). The Fund is not available for investment by the general public. Qualifying investors are subject to a lower level of protection and regulatory oversight by the MFSA than retail clients.

    This notice does not constitute, and may not be interpreted, as an offer to sell securities, nor is it an invitation, a recommendation, a solicitation, or an offer to buy securities in any jurisdiction in which such offer or solicitation is unlawful and prohibited. This notice does not constitute an offer of securities for sale in the United States and the securities referred to in this notice may not be offered or sold in the United States absent registration or an exemption from registration. Furthermore, this notice is not intended for investors or any person in any jurisdiction where the distribution of this notice or the use thereof, in any way, may be contrary to the local law or regulation. It is the responsibility of each person to inform themselves of, and to observe and comply with, all applicable laws and regulations of any relevant jurisdiction.

    The price performance of cryptocurrencies is highly volatile and unpredictable, and past price performance is no guarantee of future price performance. Investment in the Fund is speculative and involves a high degree of risk and uncertainty. The value of your investment may go down as well as up. Investors may lose some or all of their investments in the Fund.

    The approval of the Fund by the MFSA should not be construed as an endorsement of the securities offered. Potential investors should carefully consider the Fund Documents before making any investment decision to fully understand the potential risks and rewards of deciding to invest in the securities. Potential investors should also seek the appropriate advice from their financial, legal, regulatory, tax and other advisors to determine whether an investment in the Fund is suitable for them.

    The Fund website is available at: https://funds.iconicholding.com/iconic-cmbi10-short-term-momentum-index-fund/.

    The contents of this notice should not be construed as legal, tax, investment, or any other advice.

    Furthermore, the MFSA has not reviewed or approved this notice.

    About Iconic Funds GmbH:

    Iconic Funds GmbH is the holding company of a series of subsidiaries that manage and issue crypto asset investment products. Collectively, Iconic Funds GmbH and its subsidiaries are branded as 'Iconic Funds.' One such subsidiary, Iconic Funds BTC ETN GmbH, is the issuer of a physically backed Bitcoin ETP trading on the Regulated Market of the Frankfurt Stock Exchange ((ISIN: DE000A3GK2N1, TICKER:XBTI). Iconic Funds is a joint venture between Iconic Holding GmbH and Cryptology Asset Group p.l.c. (NYSE:CAP, formerly 4UD))). Iconic Holding is a portfolio company of FinLab AG (NYSE:A), leading German-VC group High-Tech Gründerfonds ('HTGF') and Cryptology Asset Group p.l.c. (NYSE:CAP, formerly 4UD))), founded by Christian Angermayer and Mike Novogratz.

    Press contact:

    Iconic Funds GmbH:
    Syuzanna Avanesyan
    [email protected]
    [email protected]
    https://funds.iconicholding.com

    SOURCE: Iconic Funds



    View source version on accesswire.com:
    https://www.accesswire.com/654258/Iconic-Funds-Receives-Regulatory-Approval-for-and-Launches-New-Fund-in-Partnership-with-Coin-Metrics

    Get the next $CAP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CAP
    $A

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    Agilent Technologies Inc.
    $A
    8/28/2024$157.00Overweight
    Wells Fargo
    Agilent Technologies Inc.
    $A
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    Agilent Technologies Inc.
    $A
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    Agilent Technologies Inc.
    $A
    6/3/2024$135.00Hold
    Jefferies
    Agilent Technologies Inc.
    $A
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    Agilent Technologies Inc.
    $A
    12/13/2023$140.00Outperform
    Wolfe Research
    Agilent Technologies Inc.
    $A
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $CAP
    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior Vice President Dimarco Bret covered exercise/tax liability with 141 shares, decreasing direct ownership by 3% to 5,475 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      7/7/25 4:04:41 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Mcdonnell Padraig sold $177,100 worth of shares (1,508 units at $117.44), decreasing direct ownership by 4% to 37,448 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      7/3/25 4:46:35 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.37% to 8,159 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      7/1/25 1:40:18 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CAP
    $A
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agilent to Showcase New Products and Innovations at HPLC 2025

      Agilent Technologies Inc. (NYSE:A) today announced that they will introduce their latest Hybrid Multisampler and highlight the new LC Single Quadrupole Mass Spectrometers at the upcoming HPLC 2025 conference in Bruges, Belgium. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can streamline operations and enhance analytical outcomes. The Agilent InfinityLab Pro iQ Series, launched at ASMS 2025, represents the next generation of LC-mass detection. With innovative hardware advancements, the series delivers enhanced sensitivity and analytical performance for oligonucleotides, therapeutic

      6/12/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Smackover Lithium's South West Arkansas Project Receives Royalty Rate Approval From the Arkansas Oil and Gas Commission

      LEWISVILLE, Ark., May 29, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is pleased to announce that the Arkansas Oil and Gas Commission ("AOGC") has unanimously approved the establishment of a 2.5% royalty rate for the Reynolds Unit for Phase I of its South West Arkansas ("SWA") Project in Lafayette and Columbia Counties. This is the first royalty rate for lithium from brine extraction that has been approved by the AOGC, establishing an important precedent for lithium development companies operating in Arkansas. SWA Lithium LLC applied for a quarterly gross royalty of

      5/29/25 8:30:27 AM ET
      $A
      $SLI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Major Chemicals
    • Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

      Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

      5/28/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CAP
    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Gonsalves Rodney (Amendment)

      4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      10/20/23 1:07:25 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

      4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

      9/29/23 4:03:46 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CAP
    $A
    SEC Filings

    See more
    • SEC Form 144 filed by Agilent Technologies Inc.

      144 - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      7/1/25 12:45:28 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Agilent Technologies Inc.

      10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      5/30/25 7:02:43 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

      5/28/25 4:06:14 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CAP
    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agilent upgraded by Barclays with a new price target

      Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

      2/10/25 6:55:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Agilent with a new price target

      Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

      8/28/24 7:20:29 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent upgraded by Citigroup with a new price target

      Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

      7/10/24 7:22:08 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CAP
    $A
    Leadership Updates

    Live Leadership Updates

    See more
    • Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

      Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

      4/24/25 8:00:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Acquire North American CDMO BIOVECTRA

      Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

      7/22/24 9:01:00 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

      Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

      6/26/24 8:00:00 AM ET
      $A
      $ANIK
      $AVNT
      $MASI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical/Dental Instruments
      Health Care

    $CAP
    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

      SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 1:27:37 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/12/24 11:54:03 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Agilent Technologies Inc.

      SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

      11/4/24 10:57:57 AM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $CAP
    $A
    Financials

    Live finance-specific insights

    See more
    • Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results

      Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended April 30, 2025, representing growth of 6.0% reported and up 5.3% on a core(1) basis compared with the second quarter of 2024. GAAP net income of $215 million; earnings per share (EPS) of $0.75, down 29% from the second quarter of 2024. Non-GAAP(2) net income of $373 million; EPS of $1.31, up 7% from the second quarter of 2024. Outlook for full 2025 fiscal year and Q3 Full-year revenue outlook is now in the range of $6.73 billion to $6.81 billion, representing a range of up 3.4% to 4.6% reported, while maintaining 2.5% to 3.5% core(1). Non-GAAP E

      5/28/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent Announces Cash Dividend of 24.8 Cents per Share

      Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted ans

      5/21/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

      Agilent Technologies Inc. (NYSE:A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Ag

      4/16/25 4:05:00 PM ET
      $A
      Biotechnology: Laboratory Analytical Instruments
      Industrials